Baillie Gifford & Co’s Twist Bioscience TWST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$112M Sell
1,086,779
-128,372
-11% -$8.35M 0.1% 127
2026
Q1
$57.7M Sell
1,215,151
-61,044
-5% -$2.74M 0.06% 143
2025
Q4
$40.5M Buy
1,276,195
+13,456
+1% +$420K 0.03% 159
2025
Q3
$35.5M Buy
1,262,739
+487,052
+63% +$14.8M 0.03% 168
2025
Q2
$28.5M Buy
775,687
+43,680
+6% +$1.51M 0.02% 172
2025
Q1
$28.7M Sell
732,007
-45,530
-6% -$2.05M 0.03% 163
2024
Q4
$36.1M Sell
777,537
-56,802
-7% -$2.57M 0.03% 156
2024
Q3
$37.7M Sell
834,339
-149,963
-15% -$7.14M 0.03% 153
2024
Q2
$48.5M Sell
984,302
-243,226
-20% -$9.92M 0.04% 142
2024
Q1
$42.1M Buy
1,227,528
+132,770
+12% +$4.79M 0.03% 152
2023
Q4
$40.4M Sell
1,094,758
-173,537
-14% -$4.01M 0.03% 162
2023
Q3
$25.7M Sell
1,268,295
-1,631
-0.1% -$35.8K 0.02% 177
2023
Q2
$26M Buy
1,269,926
+189,896
+18% +$2.84M 0.02% 175
2023
Q1
$16.3M Sell
1,080,030
-5,549
-0.5% -$123K 0.01% 196
2022
Q4
$25.8M Buy
1,085,579
+194,611
+22% +$5.64M 0.03% 178
2022
Q3
$31.4M Buy
+890,968
New +$37.8M 0.03% 170

Other funds holding TWST

Baillie Gifford & Co's TWST Position: Q2 2026 in Review

Baillie Gifford & Co reduced its Twist Bioscience (TWST) stake by 11% in Q2 2026, selling an estimated $8.35M and leaving 1,086,779 shares worth $112M. The position accounts for 0.1% of the portfolio, ranked #127.

Baillie Gifford & Co first reported a position in TWST in Q3 2022 and has held it in 16 quarters since. 337 funds tracked by Wall St. Rank hold TWST as of Q2 2026.

  • Baillie Gifford & Co held 1,086,779 shares of Twist Bioscience worth $112M as of Q2 2026.
  • Baillie Gifford & Co sold 128,372 Twist Bioscience shares in Q2 2026, an estimated $8.35M.
  • Twist Bioscience made up 0.1% of Baillie Gifford & Co's portfolio in Q2 2026, its #127 holding.
  • Baillie Gifford & Co first reported a position in Twist Bioscience in Q3 2022 and has held it in 16 quarters since.
  • 337 funds tracked by Wall St. Rank held Twist Bioscience as of Q2 2026.

Based on Baillie Gifford & Co's 13F filing for Q2 2026, filed 6 Aug 2026.